

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Henlius Biotech, Inc.**

**上海復宏漢霖生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2696)**

## **VOLUNTARY ANNOUNCEMENT 2023 FIRST QUARTERLY UPDATE**

The board of directors (the “**Board**”) of Shanghai Henlius Biotech, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) discloses the following information in respect of the Group’s selected operational and unaudited financial information for the three months ended 31 March 2023 (the “**Reporting Period**”).

In the first quarter of 2023, the Group capitalised on the established first-entrant advantages to continue to facilitate the approvals of products for new indications, align with targeted market strategies and meticulously manage the marketing personnels, actively improve the commercialisation plan, and expand the market coverage of products with a view to offering high-quality treatment options for more patients. During the Reporting Period, the Group realised Revenue of approximately RMB995.7 million, representing an increase of approximately 97.2% compared to the same period in the last year.

- HANQUYOU (trastuzumab for injection, European brand name: Zercepac<sup>®</sup>, “**HANQUYOU**”), which was launched for commercial sales in Mainland China (excluding Hong Kong, Macau and Taiwan regions, same as below) since August 2020, was the first domestic trastuzumab approved for marketing independently developed by the Group and was also the first product sold and promoted by the Group’s in-house commercialisation team in Mainland China. During the Reporting Period, HANQUYOU recorded sales revenue of approximately RMB538.6 million in Mainland China, representing a significant increase of approximately 66.7% as compared to the same period in the last year.
- HANSIZHUANG (serplulimab injection, “**HANSIZHUANG**”), which was launched for commercial sales in Mainland China since March 2022, was the first self-developed and approved bio-innovative drug of the Group. As of the date of the announcement, three indications of HANSIZHUANG have been approved for marketing, and the new drug application (NDA) for another indication has been accepted, which further enriches the Group’s commercial product line and is also expected to benefit more domestic patients. During the Reporting Period, HANSIZHUANG recorded sales revenue of approximately RMB249.8 million, of which sales in March 2023 exceeded RMB100 million, which was the first time in a single month since its commercialisation.

The Group will continue to devote to oncology, auto-immune diseases and other fields, and it will explore innovation drugs with clinical orientation by leveraging on its own innovation and R&D strength combined with external cooperation and license-in while maximizing the commercial value of biosimilars at home and abroad, so as to consolidate the internationalised capability of “integrating research, production and marketing”, and achieve steady development at a larger, international and more profitable Biopharma stage.

**The financial information contained in this announcement is prepared based on the Group’s internal management records and has not been audited or reviewed by external auditors and is therefore provided for investors’ reference only. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

On behalf of the Board  
**Shanghai Henlius Biotech, Inc.**  
**Wenjie Zhang**  
*Chairman*

Hong Kong, 16 April 2023

*As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.*